What did TRUSCREEN GROUP LIMITED announce?
TRUSCREEN GROUP LIMITED (NZX: TRU) filed “Resignation of CEO, Martin Dillon” with NZX on 1 October 2026, as an operational update announcement.
From the announcement:“TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”), a global leader in AI-enabled cervical cancer screening, advises that for personal reasons, Martin Dillon, Chief Executive Officer (CEO), has resigned from the Company with effect from 31 October 2026.”
- Which company?
- TRUSCREEN GROUP LIMITED (NZX: TRU)
- When was it filed?
- 1 October 2026
- Where is the original?
- NZX announcement
Resignation of CEO, Martin Dillon
NZX/ASX Announcement
2 October 2026
Resignation of CEO, Martin Dillon
TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”), a global leader in AI-enabled
cervical cancer screening, advises that for personal reasons, Martin Dillon, Chief Executive Officer (CEO), has
resigned from the Company with effect from 31 October 2026.
Tony Ho, Non-Executive Independent Chairman, will assume the responsibilities of Executive chairman and Interim
CEO while the Company undertakes a recruitment process for a new Chief Executive Officer.
The Board is confident that TruScreen’s executive team will continue to manage the Company’s operations and
strategic priorities during the transition period. Mr Dillon will remain a consultant to the Company to provide
support following his departure, if required.
Commenting on the announcement, Mr Ho said:
“On behalf of the Board, I thank Martin for his significant contribution to TruScreen over many years, particularly in
the past year, the opening of new markets in Central Asia, Indonesia, India, Malaysia, Thailand and greater Africa.
We respect his decision and recognise that his personal wellbeing is important. Stakeholders would be aware that
Martin lost his spouse in June 2026. We wish him every success for the future.”
The Board will provide further updates to the market as appropriate.
Approved for release by the Board.
Tony Ho
Executive Chairman
For more information, visit www.truscreen.com or contact:
Tony Ho
Executive Chairman
tonyho@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com
About TruScreen:
TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an
AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level
of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It
has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has
distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed
and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology)
China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized Prevent and
Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List,
for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines for the
screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over
200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AGL — Accordant Group Limited: Accordant Group Limited announces CEO retirement2026-09-25
“Accordant Group Limited Level 6, 51 Shortland Street, Auckland PO Box 105 675, Auckland 1143 Tel 09 526 8770 accordant.nz NZX Release 25 September 2026 ACCORDANT GROUP LIMITED (NZX: AGL) ANNOUNCES CEO RETIREMENT Accordant Group Limited (AGL) advises that Jason Cherrington…”
- BRW — Bremworth Limited: Bremworth Director Resignations2026-09-09
“MARKET RELEASE 10 September 2026 BREMWORTH DIRECTOR RESIGNATIONS Bremworth Limited (NZX:BRW) announces that independent directors Trevor Burt, Julie Bohnenn and Murray Dyer have tendered their resignation from the Board of Bremworth, effective immediately following the appro…”
- ERD — EROAD: EROAD Board Update2026-10-11
“TEL +64 9 927 4700 PO Box 305 394 FAX +64 9 927 4701 Triton Plaza, North Shore 0757 Page 1 FREE 0800 4 EROAD Auckland, New Zealand eroad.co.nz EROAD Board Update Auckland, 12 October 2026: EROAD Limited (NZX/ASX: ERD) advises that, following the appointment of David Leach…”